

## UNITED STATES PATENT AND TRADEMARK OFFICE (Case No.: 05-747)

In the Application of:  Meinke et al.	) )
Serial No.: 10/552,156	Confirmation No.: <b>4561</b>
Filing Date: October 11, 2005	) Group Art Unit: 1645
Title: Streptococcus Pyogenes Antigens	) )
	,

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### TRANSMITTAL LETTER

- 1. We are transmitting herewith the attached papers for the above-described patent application: <u>Information Disclosure Statement and return postcard</u>.
- 2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
- 3. CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 1, 2007.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

/Bv:

Kevin E. Noonan, Ph.D.

Reg. No. 35,303

Dated: May 1, 2007

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996 papersons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLO STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10552156	
Filing Date		2005-10-11	
First Named Inventor Meir		inke	
Art Unit		1645	
Examiner Name Bas		skar, Padmavathi	
Attorney Docket Numb	per	05-747	

					U.S.I	PATENTS			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup> Issue Date		ate	of cited Document			es,Columns,Lines where vant Passages or Relevant res Appear
/PB/	1	5744309				Patent Withdra	awn		
/PB/	2	4946778		1990-08	-07	Genex Corp		, , , ,	
/PB/	3	5849902		1998-12	-15	Oligos Etc. Inc.			
/PB/	4	5989912		1999-11	-23	Oligos Etc. Inc.			
If you wisl	n to ac	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	I	
			U.S.P	ATENT	APPLIC	CATION PUBI	LICATIONS		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Relev	es,Columns,Lines where vant Passages or Relevant res Appear
	1								
If you wisl	n to ac	l dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Add	d butto	on.
				FOREIG	N PAT	ENT DOCUM	ENTS		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patented Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission units) CFR 1.99)

Application Number		10552156	
Filing Date		2005-10-11	
First Named Inventor	Meinl	ke	
Art Unit		1645	
Examiner Name Bas		ar, Padmavathi	
Attorney Docket Numb	er	05-747	V-V

		MAY 0 7 2007	Attor	ney Docket Number	05-747	
		MAY 0 7 2007			·	
/PB/	1	WO 02/059148	wo	2002-08-01	Cistem Biotechnologies GmbH	
/PB/	2	A-O 464 533	EP	1992-01-08	Behringwerke AG	
/PB/	3	2045869	CA	1991-12-29	Behringwerke Aktiengesellschaft	
/PB/	4	197 42 706	DE	1999-04-15	Skerra Arne Prof Dr	
/PB/	5	0 533 838	EP	1993-03-31	Univ Colorado Foundation	
/PB/	6	98/08856	wo	1998-03-08	Furste, et al.	
/PB/	7	97/30721	wo	2007-03-19	Boehringer Ingelheim International GmbH	
/PB/	8	99/38528	wo	1999-08-05	Boehringer Ingelheim GmbH	
/PB/	9	02/13857	wo	2002-02-21	Cistem Biotechnologies GmbH	
/PB/	10	02/32451	wo	2002-04-25	Cistem Biotechnologies GmbH	
/PB/	11	01/93905	wo	2001-12-13	Cistem Biotechnologies GmbH	

					ation N	umber		10552156			
				Filing	Date			2005-10-11			
		TION DISCLOSU		First N	Named	Inventor	Mein	ke	e		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Art Ur	nit			1645			
( 1101 101 1	<b>545</b> 111	OPE	1.55,	Exam	iner Na	me	Bask	ar, Padmavathi			
		/ "	\	Attorn	ey Doc	ket Numb	er	05-747			
		MAY 0 7 2007	3)								
/PB/	12	01/54720	wo			2001-02-0		Cistem Biotechnologies GmbH			
/PB/	13	01/93903	wo			2001-12-1		Cistem Biotechnologies GmbH			
/PB/	14	02/05448	EP	EP			,	Wrong number			
/PB/	15	A 1924/2001	AU			2003-06-1	7	Intercell AG			
/PB/	16	01/24822	wo			2001-04-1		Cistem Biotechnologies GmbH			
lf you wisl	h to ac	dd additional Foreign P	atent Doc	ument	citation	informatio	n ple	ase click the Add buttor	1		
			NON-	-PATEN	NT LITE	RATURE	DOC	UMENTS			
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seria	l, symp	osium,	catalog, et	e of th	ne article (when appropr ate, pages(s), volume-is	riate), title of the item sue number(s),	<b>T</b> 5	
/PB/	1	Adamou, J., et al. (2001) Protective against Sepsi	). "Identific s" Infect In	cation an	nd Chara 9: 949-58	cterization 3	of a N	ovel Family of Pneumocoo	ccal Proteins That Are		
/PB/	2	Altschul, S., et al. (1990)	). "Basic Lo	ocal Alig	Inment S	Search Tool	" Jour	nal of Molecular Biology 2	115: 403-10		
/PB/	3	Bennett, D., et al. (1995)	). J Mol Re	ecognit 8	3: 52-8						
/PB/	4	Brown, J., et al. (2001). Systemic Streptococcus	'Immuniza pneumoni	ition with	n Compo ction" Inf	nents of Tv ect Immun	vo Iror 69: 67	n Uptake ABC Transporter 02-6	s Protects Mice against		

		*****			T			
•			Application Number		10552156			
INFOR	) R A A *	TION DISCLOSURE	Filing Date		2005-10-11			
		TION DISCLOSURE	First Named Inventor	Meinl	ke			
		NT BY APPLICANT ission under 37年末4.99)	Art Unit		1645			
( 1101 101	Jubin	The state of the s	Examiner Name	Bask	ar, Padmavathi			
			Attorney Docket Numb	er	05-747			
		MAY 0 7 2007						
/PB/	5	Burnie, J., et al. (1998). "The rena	issance of antibody therapy	" J Ant	imicrob Chemother 41: 319-22			
/PB/	6	Clackson, T., et al. (1991). Nature	352: 624-8					
/PB/	7	Devereux, J., et al. (1984). "A com 12: 387-95	nprehensive set of sequence	analy	sis programs for the VAX" Nucleic acids research			
/PB/	8	Di Guilmi, A., et al. (2002). "New a Streptococcus pneumoniae" EMB	approaches towards the ider O Reports 3: 728-34	tification	on of antibiotic and vaccine targets in			
/PB/	9	Doherty, E., et al. (2001). Annu Re	ev Biophys Biomol Struct 30	: 457-4	<b>1</b> 75			
/PB/	10	Eisenbraun, M., et al. (1993). DNA	A Cell Biol 12: 791-7					
/PB/	11	Wizemann, T., et al. (2001). "Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection" Infect Immun 69: 1593-8						
/PB/	12	Etz, H., et al. (2001). "Bacterial Phage Receptors, Versatile Tools for Display of Polypeptides on the Cell Surface" J Bacteriol 183: 6924-35						
/PB/	13	Ganz, T. (1999). "Defensins and H	Host Defense." Science 286:	420-4	21			
/PB/	14	Georgiou, G. (1997). "Display of h combinatorial libraries to live reco	eterologous proteins on the mbinant vaccines" Nature Bi	surfac	e of microorganisms: From the screening of nology 15: 29-34			

/PB/

15

Gray, B., et al. (1979). J Infect Dis 140: 979-83

### **Application Number** 10552156 Filing Date 2005-10-11 INFORMATION DISCLOSURE First Named Inventor Meinke STATEMENT BY APPLICANT Art Unit 1645 ( Not for submission under 37 CFR 1.99) **Examiner Name** Baskar, Padmavathi Attorney Docket Number 05-747 MAY 0 7 2007 16 Gray, B., et al. (1986). Pediatr Infect Dis 5: 201-7 /PB/ 17 Hashemzadeh-Bonehi, L., et al. (1998). Mol Microbiol 30: 676-678 /PB/ Hausdorff, W., et al. (2001). "Geographical differences in invasive pneumococcal disease rates and serotype 18 frequency in young children" Lancet 357: 950-2 /PB/ Tettelin, H., et al. (2001). Science 293: 498-506. 19 /PB/ Hemmer, B., et al. (1999). "Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease" 20 Nat Med 5: 1375-82 /PB/ Hoe, N., et al. (2001). "Distribution of Streptococcal Inhibitor of Complement Variants in Pharyngitis and Invasive 21 Isolates in an Epidemic of Serotype M1 Group A Streptococcus Infection" J Infect Dis 183: 633-9 /PB/ Hornef, M., et al. (2002). "Bacterial strategies for overcoming host innate and adaptive immune responses" Nat 22 Immunol 3: 1033-40 /PB/ 23 Hoskins, J., et al. (2001). "Genome of the Bacterium Streptococcus pneumoniae Strain R6" J Bacteriol 183: 5709-17 /PB/ Hyde, T., et al. (2001). "Macrolide Resistance Among Invasive Streptococcus pneumoniae Isolates" JAMA 286: 24 /PB/ 1857-62

Johanson, K., et al. (1995). "Binding Interactions of Human Interleukin 5 with Its Receptor Subunit" J Biol Chem 270:

/PB/

/PB/

25

26

9459-71

Jedrzejas, M. (2001). Microbiol Mol Biol Rev 65: 187-207

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under FF FR 1.99)

		<del></del>	
Application Number		10552156	
Filing Date		2005-10-11	
First Named Inventor	Meir	nke	
Art Unit		1645	
Examiner Name Bas		kar, Padmavathi	
Attorney Docket Number		05-747	

0,	18 g.	
 MAY	9-7-2007 y	

/PB/	27	Jones, P., et al. (1986). "Replacing the complementarity-determining regions in a human antibody with those from a mouse" Nature 321: 522-5	
/PB/	28	Kajava, A., et al. (2000). "The Net Charge of the First 18 Residues of the Mature Sequence Affects Protein Translocation across the Cytoplasmic Membrane of Gram-Negative Bacteria" J Bacteriol 182: 2163-9	
/PB/	29	Kohler, G., et al. (1975). "Continuous cultures of fused cells secreting antibody of predefined specificity " Nature 256: 495-7	
/PB/	30	Kolaskar, A., et al. (1990). "A semi-empirical method for prediction of antigenic determinants on protein antigens" FEBS Lett 276: 172-4	
/PB/	31	Lewin, A., et al. (2001). "Ribozyme gene therapy: applications for molecular medicine" Trends Mol Med 7: 221-8	
/PB/	32	Marks, J., et al. (1992). Biotechnology (N Y) 10: 779-83	
/PB/	33	McCafferty, J., et al. (1990). Nature 348: 552-4	
/PB/	34	McCormick, A., et al. (2003). "Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States" Nat Med 9: 424-30	
/PB/	35	McDaniel, L., et al. (1991). "PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type" Infect Immun 59: 222-8	
/PB/	36	Navarre, W., et al. (1999). Microbiol Mol Biol Rev 63: 174-229	
/PB/	37	Okano, H., et al. (1991). J Neurochem 56: 560-7	

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Filing Date First Named Inventor Meinke

**Application Number** 

**Examiner Name** 

Art Unit

10552156 2005-10-11

1645

(Not for submission under 35 CFR 1.99)

Baskar, Padmavathi

		MAY 0 7 2007	Attorney Docket Number	05-747								
		MIN (2)										
	Γ	TA FRANCISCO										
/PB/	38	Tourdot, S., et al. (2000). "A general implication in the identification of co	Tourdot, S., et al. (2000). "A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes" Eur J Immunol 30: 3411-21.									
/PB/	39	Orange, M., et al. (1993). Pediatr Infect Dis J 12: 244-6										
/PB/	40	Pelton, S., et al. (2003). "Pneumoc Interscience Conference on Antimi	Pelton, S., et al. (2003). "Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st interscience Conference on Antimicrobial Agents and Chemotherapy" Vaccine 21: 1562-71									
/PB/	41	Phillips-Quagliata, J., et al. (2000). Receptor" J Immunol 165: 2544-55	Phillips-Quagliata, J., et al. (2000). "The IgA/IgM Receptor Expressed on a Murine B Cell Lymphoma Is Poly-Ig Receptor" J Immunol 165: 2544-55									
/PB/	42	Rammensee, H., et al. (1999). "SY	FPEITHI: database for MHC ligan	nds and peptide motifs" Immunogenetics 50: 213-9								
/PB/	43	Roche, H., et al. (2003). "Regions of in a Murine Infection Model" Infect	of PspA/EF3296 Best Able To Elic Immun 71: 1033-41	cit Protection against Streptococcus pneumoniae								
/PB/	44			Activity Against Streptococcus pneumoniae in Antibody Avidity" Clin Infect Dis 29: 281-8								
/PB/	45	Rosenow, C., et al. (1997). "Contril immunogenicity of Streptococcus p		oteins to adherence, colonization and 9-29								
/PB/	46	Seeger, C., et al. (1984). "The Clor Acad Sci U S A 81: 5849-52	ned Genome of Ground Squirrel H	depatitis Virus is Infectious in the Animal" Proc Natl								
/PB/	47	Shibuya, A., et al. (2000). "Fc rece	ptor mediates endocytosis of IgM-	-coated microbes" Nature Immunology 1: 441-6								
/PB/	48	Sekrra, A. et al. (1994). "Use of the fragment in Escherichia coli" 151: 1		itly regulated production of a murine antibody								

						****			WOMAN CO.	
•	·					Application Number		10552156		
INICOD			l Dicc	N 0011	<b>D</b> E	Filing Date		2005-10-11		
				CLOSU	·	First Named Inventor	Mein	ke		
				PLICA		Art Unit	•	1645		
(1101101	Jubiii	1331011	O	FER 1.	33)	Examiner Name	Bask	ar, Padmavathi		
				18	\	Attorney Docket Num	ber	05-747		
			13	0 7 2007 g	3					
/PB/	49	Talkir	ngton, D. et al (1996) Microb Pathog 21: 17-22							
/PB/	50	Tang,	, D., et al	. (1992). Na	ature 356:	152-4.				
If you wis	h to a	dd add	litional n	on-patent	literature	document citation infe	ormatio	n please click the Add I	outton	
						EXAMINER SIGNA	TURE			
Examiner	Signa	ture	,	/Padmavathi	Baskar/			Date Considered	02/19/2008	
								mance with MPEP 609 th next communication		
Standard S	T.3). <sup>3</sup> F cument	or Japa by the a	anese pate appropriate	ent document e symbols as	ts, the indic	cation of the year of the reigi	of the E	office that issued the docume imperor must precede the se ard ST.16 if possible. <sup>5</sup> Appli	rial number of the patent do	cument.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 27 SFR 1.99) Filing Date 2005-10 First Named Inventor Meinke Art Unit 1645

Application Number		10552156	
Filing Date		2005-10-11	
First Named Inventor	Meinke		
Art Unit		1645	
Examiner Name	Baskar, Padmavathi		
Attorney Docket Number		05-747	

MAY 0 7 2007

#### **CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

#### **SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Date (YYYY-MM-DD)	
Name/Print	Registration Number	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**